Theragenics Corporation is a medical device company serving the surgical products and cancer treatment markets. The Company operates in two segments: brachytherapy seed business and the surgical products business. In the brachytherapy seed business, the Company produces, markets and sells TheraSeed, its palladium-103 prostate cancer treatment device; I-Seed, its iodine-125-based prostate cancer treatment device; and other related products and services. The Company’s surgical products business consists of wound closure vascular access and specialty needle products. Wound closure includes sutures, needles and other surgical products with applications in, among other areas, urology, veterinary, cardiology, orthopedics, plastic surgery and dental. Vascular access includes introducers and guidewires used in the interventional radiology, interventional cardiology and vascular surgery markets. On July 28, 2008, the Company completed the acquisition of NeedleTech Products, Inc.